Nortriptyline, sold under the brand name Aventyl, among others, is a tricyclic antidepressant. This medicine is also sometimes used for neuropathic pain, attention deficit hyperactivity disorder, smoking cessation and anxiety. Mechanistically it primarily inhibits neuronal reuptake of norepinephrine and, to a lesser extent, serotonin, while exhibiting antagonism at muscarinic acetylcholine, H1 histamine and alpha1 adrenergic receptors, which contributes to its anticholinergic, sedative and orthostatic effects. Nortriptyline is well absorbed after oral administration with Tmax typically within 1 to 4 hours, undergoes significant first pass metabolism mainly via CYP2D6 to active and inactive metabolites including 10-hydroxynortriptyline, is highly protein bound and has an elimination half-life commonly reported in the range of approximately 18 to 44 hours in adults; therapeutic drug monitoring with target plasma concentrations around 50 to 150 ng/mL can guide dosing, and typical adult oral dose ranges and titration require individualization with attention to cardiac screening, drug interactions and contraindications.
Parent: Amitriptyline/ Nortriptyline/ Cyproheptadine
Parent: Nortriptyline/ Amitriptyline
Parent: Nortriptyline / Amitriptyline
Parent: Nortriptyline
Parent: Nortriptyline
Parent: Nortriptyline Hydrochloride / Nortriptyline
Parent: Nortriptyline
Parent: Nortriptyline
Parent: Nortriptyline
![5-(3-(Methylamino)propyl)-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ol](https://veeprho.com/wp-content/uploads/2024/10/VE0021803-5-3-Methylamino-propyl-10-11-dihydro-5H-dibenzoa-d-7-annulen-5-ol.png "5-(3-(Methylamino)propyl)-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ol")
Parent: Nortriptyline
Pharmaceutical grade nortriptyline is manufactured and controlled to limit related compounds, degradation products and residual process impurities; known related substances include N-oxides, hydroxylated or demethylated analogs such as 10-hydroxynortriptyline, trace amounts of parent tricyclic analogs and potential ring-modified byproducts. Typical specification approaches used by manufacturers and pharmacopeial monographs set individual known related compound limits in the low parts-per-thousand to parts-per-ten-thousand range, commonly with individual impurity acceptance criteria around 0.1 to 0.2 percent by mass and total impurities limited to approximately 0.5 to 1.0 percent, while reporting and identification thresholds follow ICH guidance and are often at or below 0.05 to 0.1 percent depending on exposure; impurity profiling is performed by validated chromatographic and mass spectrometric methods, and residual solvents and elemental impurities are controlled to limits consistent with ICH Q3C and Q3D.
Nortriptyline is approved and commonly used for major depressive disorder and is prescribed off label for neuropathic pain, migraine prophylaxis, certain chronic pain syndromes, and in some cases for attention deficit hyperactivity disorder and smoking cessation support; choice and dosing depend on the clinical indication and patient factors.
No, nortriptyline is not classified as a sleeping pill; however, because of antihistaminic and anticholinergic properties it can cause sedation and be used to improve sleep as a secondary effect in some patients, but it is not a hypnotic and should not be used solely for short term insomnia without medical supervision.
Nortriptyline can be considered higher risk than many newer antidepressants due to its anticholinergic effects, potential for cardiotoxicity at overdose or in vulnerable patients, drug interaction potential especially via CYP2D6, and need for dose adjustments in elderly or medically complex patients; monitoring, ECG when indicated and careful dose titration reduce risk.
Common adverse effects include dry mouth, constipation, urinary retention, blurred vision, sedation, orthostatic hypotension and weight changes due to anticholinergic and antihistaminic activity; more serious effects can include cardiac conduction abnormalities, tachycardia, worsening of glaucoma or urinary retention, seizures in predisposed individuals, and risk of severe toxicity in overdose, so clinicians weigh benefits versus risks and monitor accordingly.
